Metastases to peritoneum – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:03:51 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Metastases to peritoneum – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Evaluation of 68Ga-FAPI PET/CT scan effectiveness in monitoring treatment response in patients with peritoneal metastases receiving intraperitoneal chemotherapy https://clinicaltrials.eu/trial/evaluation-of-68ga-fapi-pet-ct-scan-effectiveness-in-monitoring-treatment-response-in-patients-with-peritoneal-metastases-receiving-intraperitoneal-chemotherapy/ Wed, 29 Apr 2026 15:07:06 +0000 https://clinicaltrials.eu/trial/evaluation-of-68ga-fapi-pet-ct-scan-effectiveness-in-monitoring-treatment-response-in-patients-with-peritoneal-metastases-receiving-intraperitoneal-chemotherapy/ This study focuses on patients with peritoneal metastases, a condition where cancer cells spread to the lining of the abdominal cavity. The research evaluates a new imaging method using 68Ga-FAPI-46, which is a special solution given through an intravenous injection into a vein. This imaging agent helps create detailed pictures of the inside of the body when used with special scanning equipment.

The purpose of the study is to determine how well PET/CT scans using this imaging solution can show how tumors are responding to treatment in patients receiving chemotherapy directly into their abdomen. During the study, participants will receive the imaging solution and undergo scanning procedures to create detailed pictures of their cancer before and after treatment.

The treatment involves giving chemotherapy medication directly into the abdominal cavity, which may be combined with regular chemotherapy given through the bloodstream. The study will last approximately two years, during which patients will receive up to two doses of the imaging solution, with each dose calculated based on body weight.

]]> Study on Human Albumin Solution and Ringer Lactate for Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy https://clinicaltrials.eu/trial/study-on-human-albumin-solution-and-ringer-lactate-for-patients-undergoing-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy/ Wed, 29 Apr 2026 15:03:05 +0000 https://clinicaltrials.eu/trial/study-on-human-albumin-solution-and-ringer-lactate-for-patients-undergoing-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy/ This clinical trial is focused on patients undergoing a specific type of cancer treatment known as cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). This treatment is often used for patients with cancer that has spread to the lining of the abdomen, such as from gynecological or digestive origins. The study aims to evaluate the effectiveness of using a combination of 20% human albumin solution and Ringer Lactate compared to Ringer Lactate alone for fluid replacement during this surgery.

The purpose of the study is to assess how well the combination of these fluids works in improving recovery after surgery. Participants will be randomly assigned to receive either the combination of human albumin solution and Ringer Lactate or Ringer Lactate alone. The study will monitor the participants’ recovery over a period of 28 days after the surgery, looking at various outcomes such as complications, the need for additional medical support, and overall recovery.

Throughout the study, participants will receive regular check-ups to monitor their health and any potential side effects. The trial will help determine if the addition of human albumin solution to the fluid replacement strategy can lead to better outcomes for patients undergoing this intensive cancer treatment. The study is expected to continue until 2027, with recruitment starting in 2025.

]]> Study of Irinotecan with FOLFOX and Bevacizumab for Patients with Unresectable Colorectal Cancer Metastases https://clinicaltrials.eu/trial/study-of-irinotecan-with-folfox-and-bevacizumab-for-patients-with-unresectable-colorectal-cancer-metastases/ Wed, 29 Apr 2026 14:59:56 +0000 https://clinicaltrials.eu/trial/study-of-irinotecan-with-folfox-and-bevacizumab-for-patients-with-unresectable-colorectal-cancer-metastases/ This clinical trial is focused on studying a treatment for patients with unresectable colorectal peritoneal metastases, which is a condition where cancer from the colon or rectum has spread to the lining of the abdomen and cannot be removed with surgery. The treatment being tested involves the use of irinotecan hydrochloride, a medication that is typically used in chemotherapy, but in this study, it is administered directly into the abdominal cavity. This method is known as intraperitoneal infusion. The study also includes the use of a combination of other chemotherapy drugs known as FOLFOX and a medication called bevacizumab.

The purpose of the study is to explore how effective this treatment combination is in improving the survival of patients with this type of cancer. Participants in the study will receive the treatment over a period of time, and their health will be monitored to see how the cancer responds. The study aims to determine if this approach can help control the cancer and improve the quality of life for patients.

Throughout the study, patients will receive regular check-ups and assessments to track their progress and any side effects they may experience. The study is designed to gather important information that could lead to better treatment options for people with unresectable colorectal peritoneal metastases in the future.

]]> Study on Bevacizumab and Drug Combination for Patients with Resectable Colorectal Peritoneal Metastases https://clinicaltrials.eu/trial/study-on-bevacizumab-and-drug-combination-for-patients-with-resectable-colorectal-peritoneal-metastases/ Wed, 29 Apr 2026 14:57:56 +0000 https://clinicaltrials.eu/trial/study-on-bevacizumab-and-drug-combination-for-patients-with-resectable-colorectal-peritoneal-metastases/ This clinical trial is focused on studying treatments for peritoneal metastases that originate from colorectal cancer. Peritoneal metastases occur when cancer cells spread to the lining of the abdomen. The study involves a combination of surgery and various medications to see if this approach can improve patient outcomes. The medications being tested include Avastin (bevacizumab), Leucovorin-Teva (folinic acid), Oxaliplatin Eugia (oxaliplatin), Xeloda (capecitabine), 5-Fluorouracil Sandoz (fluorouracil), and Irinotecan Mylan Generics (irinotecan hydrochloride trihydrate). These medications are used in combination to target cancer cells and are administered either intravenously or orally.

The purpose of this study is to compare the effectiveness of chemotherapy and immunotherapy given before and after surgery with the standard approach of surgery alone. The study aims to determine if the additional treatments can improve overall survival rates for patients. Participants will receive treatment over a period of up to 12 months, with regular monitoring to assess the safety and effectiveness of the therapies. The study is designed to explore whether the combination of these treatments can provide better outcomes than surgery alone.

Throughout the study, participants will undergo various procedures, including HIPEC (Hyperthermic Intraperitoneal Chemotherapy), which involves applying heated chemotherapy directly into the abdominal cavity during surgery. This approach aims to kill any remaining cancer cells after the tumor has been surgically removed. The trial is structured to ensure that all participants receive the best possible care while contributing to important research that could benefit future patients with similar conditions.

]]> Study of Radspherin® for Patients with Peritoneal Cancer from Colorectal Cancer After Surgery and Chemotherapy https://clinicaltrials.eu/trial/study-of-radspherin-for-patients-with-peritoneal-cancer-from-colorectal-cancer-after-surgery-and-chemotherapy/ Wed, 29 Apr 2026 14:30:14 +0000 https://clinicaltrials.eu/trial/study-of-radspherin-for-patients-with-peritoneal-cancer-from-colorectal-cancer-after-surgery-and-chemotherapy/ This clinical trial is focused on studying a condition known as peritoneal carcinomatosis, which occurs when cancer cells spread to the lining of the abdominal cavity. This condition is often associated with colorectal cancer, a type of cancer that begins in the colon or rectum. The trial will investigate the effects of a treatment called Radspherin, which is a suspension for injection containing radium-224 adsorbed in calcium carbonate microparticles. This treatment is designed to be administered directly into the abdominal cavity, a method known as intraperitoneal use.

The purpose of the study is to compare the time patients live without their disease getting worse after receiving Radspherin compared to those who do not receive this treatment. Participants in the study will have undergone a procedure called cytoreductive surgery, which aims to remove as much of the tumor as possible, followed by hyperthermic intraperitoneal chemotherapy (HIPEC), a treatment that involves heating chemotherapy drugs and delivering them directly into the abdominal cavity. The study will follow participants over a period of time to monitor their health and any changes in their condition.

Throughout the study, participants will undergo regular assessments, including imaging tests like CT or MRI, to evaluate the progression of their disease. The study will also track overall survival, changes in specific blood markers, and any side effects experienced by participants. The goal is to gather information on the safety and effectiveness of Radspherin in treating peritoneal carcinomatosis from colorectal cancer.

]]> Study of Radium-224 in Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer with Peritoneal Metastasis Undergoing Chemotherapy and Surgery https://clinicaltrials.eu/trial/study-of-radium-224-in-patients-with-advanced-ovarian-fallopian-tube-or-peritoneal-cancer-with-peritoneal-metastasis-undergoing-chemotherapy-and-surgery/ Wed, 29 Apr 2026 14:30:06 +0000 https://clinicaltrials.eu/trial/study-of-radium-224-in-patients-with-advanced-ovarian-fallopian-tube-or-peritoneal-cancer-with-peritoneal-metastasis-undergoing-chemotherapy-and-surgery/ This clinical trial is focused on studying certain types of advanced cancers that affect the ovaries, fallopian tubes, or the lining of the abdomen, known as the peritoneum. These cancers are specifically referred to as high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer. The study is investigating a treatment called Radspherin, which is a type of therapy that involves injecting a special substance into the abdominal area. This substance contains radium-224, a radioactive element, which is absorbed in tiny particles of calcium carbonate. The aim is to see if this treatment can help patients who are scheduled to receive chemotherapy and surgery to remove as much of the cancer as possible.

The purpose of the study is to compare how long patients can live without their cancer getting worse when treated with Radspherin compared to those who do not receive this treatment. Patients participating in the study will be randomly assigned to either receive the treatment or not. The study will follow their progress over time to see how the treatment affects their cancer. This includes regular check-ups and imaging tests like CT or MRI scans to monitor the cancer’s status.

Throughout the study, researchers will also look at other factors, such as overall survival rates, the time until further cancer treatment is needed, and changes in certain cancer markers in the blood. Additionally, the study will assess how the treatment impacts patients’ quality of life through questionnaires. The goal is to gather comprehensive data to understand the potential benefits and effects of Radspherin in treating these advanced cancers.

]]> Study on the Effectiveness of Heated Chemotherapy with Mitomycin-C for Patients with Colon Cancer Spread to the Peritoneum After Surgery https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-heated-chemotherapy-with-mitomycin-c-for-patients-with-colon-cancer-spread-to-the-peritoneum-after-surgery/ Wed, 29 Apr 2026 14:29:36 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-heated-chemotherapy-with-mitomycin-c-for-patients-with-colon-cancer-spread-to-the-peritoneum-after-surgery/ This clinical trial is focused on studying a treatment for patients with peritoneal metastases of colorectal cancer. The treatment being tested is called hyperthermic intraoperative chemotherapy (HIPEC) using a drug named Mitomycin-C. This drug is administered directly into the abdominal area during surgery after the visible cancer has been removed. The purpose of the study is to evaluate whether this treatment can help reduce the recurrence of cancer in the abdominal area.

Participants in the study will be divided into two groups. One group will receive the HIPEC treatment with Mitomycin-C, while the other group will not receive this additional treatment. The study will monitor the participants over several years to see if there are differences in how often the cancer returns in the abdomen. The study will also look at overall cancer recurrence, survival rates, and any complications that may arise after the surgery.

Throughout the study, the quality of life of the participants will be assessed using specific questionnaires. The study aims to provide valuable information on whether adding HIPEC with Mitomycin-C to the surgical treatment can improve outcomes for patients with this type of cancer. The study is expected to continue until 2027, with participants being monitored for up to three years after their treatment.

]]> Study on Irinotecan and mFOLFOX4-Bevacizumab for Patients with Resectable Colorectal Peritoneal Metastases https://clinicaltrials.eu/trial/study-on-irinotecan-and-mfolfox4-bevacizumab-for-patients-with-resectable-colorectal-peritoneal-metastases/ Wed, 29 Apr 2026 14:23:16 +0000 https://clinicaltrials.eu/trial/study-on-irinotecan-and-mfolfox4-bevacizumab-for-patients-with-resectable-colorectal-peritoneal-metastases/ This clinical trial is focused on studying a treatment for patients with colorectal cancer that has spread to the lining of the abdomen, known as peritoneal metastases. The study involves a combination of medications, including irinotecan, oxaliplatin, folinic acid, fluorouracil, and bevacizumab. These medications are used as part of a chemotherapy regimen to treat the cancer. The purpose of the study is to determine if this combination of treatments is feasible before patients undergo a surgical procedure called CRS-HIPEC, which stands for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Participants in the study will receive the chemotherapy drugs through an infusion, which means the medication is delivered directly into the bloodstream or the abdominal cavity. The treatment will be given over several cycles, with each cycle lasting a few weeks. The study will monitor how well patients tolerate the treatment and whether they can complete all the planned cycles of chemotherapy before undergoing the CRS-HIPEC procedure. The study will also assess the response of the cancer to the treatment using imaging tests and other evaluations.

The trial aims to gather information on the safety and effectiveness of this treatment approach for patients with colorectal cancer that has spread to the peritoneum. It will also look at the impact of the treatment on patients’ quality of life and their ability to remain free of disease after the surgery. The study is expected to continue for several years, with follow-up assessments to track the long-term outcomes for participants.

]]>